Tour de Cure runs along the Genesee River, hosts happy hour
The group helped raise funds for the upcoming American Diabetes Association Finger Lakes Tour de Cure.
They rode along the Genesee River and even hosted a happy hour at Three Heads Brewing all to help train those interested in participating in this year's tour.
Organizers said there were two training routes Monday evening, and they plan on bringing more members than ever to this year's fight for diabetes research, education and advocacy. About 60 cyclists joined in Monday.
The annual Tour de Cure will be held on June 7.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Sana Biotechnology (SANA) Rated ‘Market Perform' on Diabetes Program Prospects
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the penny stocks that will skyrocket. On June 24, analysts at Citizens JMP reiterated a 'Market Outperform' rating on the stock and a $5 price target. The positive stance follows the updating of clinical data from a diabetes program. Elena Pavlovich/ Clinical trial results presented at the American Diabetes Association conference from the UP421 cadaveric pancreatic islet cell program demonstrated that the treatment was safe and well-tolerated in patients with Type 1 diabetes. According to Citizens JMP, six-month follow-up data from a modified pancreatic islet cell program should validate Sana's HIP platform in Type 1 diabetes. The research firm is also optimistic about Sana Biotechnology's SC291 program for autoimmune disease, which is expected to be available in 2025. Sana Biotechnology, Inc. (NASDAQ:SANA) develops engineered cells as medicines for patients. It aims to repair and control genes, replace missing or damaged cells, and make therapies broadly accessible. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS)
Fractyl Health, Inc. (NASDAQ:GUTS) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 18, Canaccord Genuity reiterated its 'Buy' rating on Fractyl Health, Inc. (NASDAQ:GUTS) with a price target of $12. This decision came after the company had shared new data from its Phase 3 trial of its lead product candidate, Revita. A medical laboratory surrounded by advanced equipment, symbolizing the company's cutting-edge innovation in healthcare. Canaccord Genuity had follow-up discussions with several physicians following the data presented by Fractyl Health, Inc. (NASDAQ:GUTS) from the open-label group of its ongoing Phase 3 trial for Revita in weight maintenance at the American Diabetes Association meeting. These physicians who were consulted by the investment firm were all from large academic hospitals in the US. The physicians had different opinions on the mechanism behind the Revita procedure and the potential market size. However, they all agreed that controlled data is needed to fully assess the clinical profile. The physicians said the main concern is the durability of the effect. Canaccord pointed out that even conservative market share estimates from the physicians surpassed the firm's current modeling expectations. Canaccord Genuity expects Revita to reach 1% peak penetration in the weight maintenance population with a 60% probability of success. The investment firm projects that peak sales could reach $400 million in 2031. Fractyl Health, Inc. (NASDAQ:GUTS) is a metabolic therapeutics company focused on pursuing therapies that target root causes of obesity and type 2 diabetes. While we acknowledge the potential of GUTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Hamilton Spectator
6 days ago
- Hamilton Spectator
Continuous glucose monitors are in vogue. But do you really need to track your blood sugar?
A quarter-size device that tracks the rise and fall of sugar in your blood is the latest source of hope — and hype — in the growing buzz around wearable health technology. Continuous glucose monitors, small patches that provide 24-hour insight into concentrations of sugar in the blood, could be a tool for Americans to 'take control over their own health,' Health Secretary Robert F. Kennedy Jr. recently told federal lawmakers. 'They can take responsibility,' Kennedy said. 'They can begin to make good judgments about their diet, about their physical activity, about the way they live their lives.' The devices have lifesaving benefits for people with diabetes, the disease caused when blood sugar remains high because their bodies don't make enough insulin or become resistant to it. The condition, which affects more than 38 million people in the U.S., raises the risk of serious health problems such as heart and kidney disease and vision loss. But the devices have surged in popularity among people without diabetes. Sales have been driven by high-profile marketers such as Casey Means , the nominee for U.S. surgeon general . There's scant evidence the monitors are useful for people with normal blood sugar levels, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Healthy bodies can effectively regulate glucose after meals and provide the energy they need to function. Glucose monitors may lead people to misinterpret normal swings in blood sugar that happen after eating or activity. In addition, the devices can be 'notoriously inaccurate,' providing misleading readings, she said. 'The problem with wearing these is that you can just be zooming in on and creating pathology when it's not there,' Dushay said. Here's what you need to know about the devices: Here's what a continuous glucose monitor does The device is a small patch, about the size of two stacked quarters, usually placed on the upper arm or stomach. It uses a needle to painlessly pierce the skin for a tiny sensor. The sensor measures the glucose in fluid under the skin, delivering a signal every few minutes to a phone app or a handheld display. The apps typically record blood sugar levels and help people track the foods they eat and how they impact those levels. When healthy people eat a meal that contains carbohydrates, their blood sugar rises, peaks and falls in response to the food. A healthy fasting blood glucose level for a person without diabetes is roughly 70 milligrams per deciliter to 99 milligrams per deciliter. A range from 100 to 126 milligrams per deciliter indicates prediabetes and above 126 milligrams per deciliter indicates diabetes, according to the American Diabetes Association. In adults without diabetes, blood sugar levels can climb to 140 milligrams per deciliter or more within an hour of a meal, before falling back to baseline levels within two or three hours, according to the association. It's a sign the body is processing sugar normally. Continuous glucose monitors have been available since the late 1990s For decades, these devices were available only for people with diabetes. The monitors revolutionized care by allowing more precise adjustment of insulin used to treat diabetes and giving people the ability to modify meals and activity more accurately. Last year, the U.S. Food and Drug Administration approved the first over-the-counter monitors. Since then, many companies have emerged to market them, claiming to provide intensive, individualized health monitoring. Cost is generally about $100 a month. They've really caught on with consumers curious about how food and activity affect their blood sugar levels. For instance, Noom, the weight-loss and fitness app, launched a blood glucose feature last year that has proven extremely popular, said Alexander Fabry, a company executive. 'Of the people who are using a CGM, the vast majority of them don't have a diabetes diagnosis,' he said. Who can use the monitors? The devices have been lifesaving for people with diabetes. And they can be helpful for people with risk factors for the disease, including obesity, prediabetes, a history of gestational diabetes or a family history of the condition. The devices can allow users to see how specific food and activity choices affect their blood sugar in near real-time, said Dr. Alaina Vidmar, a pediatric obesity specialist at Children's Hospital Los Angeles. 'After a large meal, you may watch your blood sugar go up and sort of learn something about yourself,' Vidmar said. 'For example, I drink a sugar-sweetened soda and my blood sugar goes up really high, really fast. And maybe I don't feel as good, right?' What are the cautions? People without risk factors for diabetes may turn to the monitors just because they're curious, said Dr. David Kessler. A former FDA commissioner, Kessler doesn't have diabetes, but he wore a monitor for a couple months during research for his recent book, 'Diet, Drugs and Dopamine.' 'I think it's a very interesting tool to experiment with if you're so inclined,' Kessler said. But, he noted, the devices can't be used to diagnose or treat disease. Even experts don't agree on how to interpret or provide health advice for people without diabetes based on blood sugar data. 'No one knows what's optimal in the nondiabetic state,' he said. Before using a monitor, Dushay asks patients to consider their motives. 'What do you think you're going to get from the data?' she said. 'What is to be gained from wearing that monitor?' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
